Trials / Unknown
UnknownNCT04948125
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma
Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma Progressed After Immune Checkpoint Inhibitors:a Single-arm,Open-label Prospective Trial
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Henan Cancer Hospital · Other Government
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a phase II study, to evaluate the effectiveness and safety of Camrelizumab combined with apatinib for advanced gastric or esophagogastric adenocarcinoma progressed after immune checkpoint inhibitors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | camrelizumab | 200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle. |
| DRUG | Apatinib Mesylate | 250 mg qd |
Timeline
- Start date
- 2021-04-28
- Primary completion
- 2022-06-03
- Completion
- 2023-08-03
- First posted
- 2021-07-01
- Last updated
- 2021-07-01
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04948125. Inclusion in this directory is not an endorsement.